Advertisement
Advertisement
MYGN
Myriad Genetics Inc
4.67
USDSponsored
-0.08
-1.79%
Mar 20, 14:05 UTC -4
Open
MYGN Earnings Reports
Positive Surprise Ratio
MYGN beat 18 of 21 last estimates.
86%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$206.43M
/-$0.06
Implied change from Q4 25 (Revenue/ EPS)
-1.60%
/-250.00%
Implied change from Q1 25 (Revenue/ EPS)
+5.38%
/+100.00%
Myriad Genetics Inc earnings per share and revenue
On Feb 23, 2026, MYGN reported earnings of 0.04 USD per share (EPS) for Q4 25, beating the estimate of -0.01 USD, resulting in a 368.46% surprise. Revenue reached 209.80 million, compared to an expected 211.51 million, with a -0.81% difference. The market reacted with a -1.99% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 13 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 206.43 million USD, implying an decrease of -250.00% EPS, and decrease of -1.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.37
Surprise
-706.10%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
XOMA Royalty Corporation Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.15
Actual
$0.12
Surprise
+175.90%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.07
Surprise
-1472.55%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
FAQ
What were Myriad Genetics Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Myriad Genetics Inc reported EPS of $0.04, beating estimates by 368.46%, and revenue of $209.80M, -0.81% below expectations.
How did the market react to Myriad Genetics Inc's Q4 2025 earnings?
The stock price moved down -1.99%, changed from $6.04 before the earnings release to $5.92 the day after.
When is Myriad Genetics Inc expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Myriad Genetics Inc's next earnings report?
Based on 13
analysts, Myriad Genetics Inc is expected to report EPS of -$0.06 and revenue of $206.43M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement